PriceTargets.com logo

Celldex Therapeutics - CLDX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $43.80
  • Forecasted Upside: 47.97%
  • Number of Analysts: 11
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$29.60 As of 12/4/2025 05:00 PM ET
▲ +1.79 (6.44%)

This chart shows the closing price for CLDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celldex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLDX

Analyst Price Target is $43.80
▲ +47.97% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Celldex Therapeutics in the last 3 months. The average price target is $43.80, with a high forecast of $67.00 and a low forecast of $21.00. The average price target represents a 47.97% upside from the last price of $29.60.

This chart shows the closing price for CLDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Celldex Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
11/5/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2025BarclaysLower TargetUnderweight ➝ Underweight$25.00 ➝ $21.00
10/21/2025MizuhoInitiated CoverageOutperform$48.00
10/20/2025MizuhoUpgradeStrong-Buy
10/13/2025BarclaysInitiated CoverageUnderweight$25.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/17/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$62.00
8/20/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$44.00 ➝ $38.00
8/20/2025CitigroupLower TargetBuy ➝ Buy$56.00 ➝ $48.00
8/20/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$64.00 ➝ $62.00
8/20/2025HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $42.00
6/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00
5/9/2025UBS GroupLower TargetBuy ➝ Buy$44.00 ➝ $38.00
5/9/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$36.00 ➝ $31.00
5/9/2025Morgan StanleyLower TargetOverweight ➝ Overweight$46.00 ➝ $43.00
5/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/28/2025Canaccord Genuity GroupInitiated CoverageBuy$64.00
3/20/2025Morgan StanleyInitiated CoverageOverweight$46.00
3/3/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$42.00 ➝ $36.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
2/13/2025UBS GroupInitiated CoverageBuy$44.00
1/29/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
1/2/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
12/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
11/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
10/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
10/7/2024CitigroupInitiated CoverageBuy$70.00
9/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$45.00
9/27/2024Wolfe ResearchDowngradeOutperform ➝ Peer Perform
9/26/2024Wells Fargo & CompanyUpgradeHold ➝ Strong-Buy
9/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
9/25/2024Wolfe ResearchReiterated RatingOutperform ➝ Outperform$51.00 ➝ $51.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
8/12/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$35.00 ➝ $37.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
7/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
7/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
6/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
6/18/2024Stifel NicolausInitiated CoverageBuy$58.00
6/11/2024Wolfe ResearchInitiated CoverageOutperform$51.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00
4/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00
2/27/2024GuggenheimBoost TargetBuy ➝ Buy$72.00 ➝ $90.00
12/20/2023TD CowenInitiated CoverageOutperform
11/10/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$27.00
11/6/2023HC WainwrightBoost TargetBuy ➝ Buy$73.00 ➝ $80.00
11/3/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$54.00 ➝ $52.00
10/12/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00
9/27/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00
8/22/2023Wells Fargo & CompanyInitiated CoverageUnderweight
8/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$54.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$73.00
5/5/2023Cantor FitzgeraldLower Target$55.00 ➝ $54.00
3/1/2023HC WainwrightReiterated RatingBuy$73.00
11/11/2022GuggenheimLower TargetBuy$68.00 ➝ $63.00
8/9/2022Leerink PartnersLower TargetOutperform$68.00 ➝ $64.00
7/1/2022HC WainwrightBoost TargetBuy$60.00 ➝ $73.00
3/1/2022Cantor FitzgeraldReiterated RatingOverweight
9/17/2021Jefferies Financial GroupInitiated CoverageBuy$66.00
9/13/2021HC WainwrightBoost TargetBuy$54.00 ➝ $60.00
9/10/2021Leerink PartnersInitiated CoverageOutperform$68.00
8/6/2021HC WainwrightBoost TargetBuy$50.00 ➝ $54.00
7/22/2021GuggenheimInitiated CoverageBuy$66.00
7/12/2021HC WainwrightBoost TargetBuy$36.00 ➝ $50.00
2/23/2021HC WainwrightBoost TargetBuy$25.00 ➝ $36.00
2/23/2021Cantor FitzgeraldBoost TargetOverweight$22.00 ➝ $35.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 21 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 29 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 15 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 7 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 14 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 14 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $29.60
Low: $27.68
High: $29.71

50 Day Range

MA: $26.05
Low: $22.67
High: $29.60

52 Week Range

Now: $29.60
Low: $14.40
High: $29.71

Volume

741,926 shs

Average Volume

754,121 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Celldex Therapeutics?

The following equities research analysts have issued stock ratings on Celldex Therapeutics in the last year: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Mizuho, Morgan Stanley, The Goldman Sachs Group, Inc., UBS Group AG, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for CLDX.

What is the current price target for Celldex Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Celldex Therapeutics in the last year. Their average twelve-month price target is $43.80, suggesting a possible upside of 48.0%. Cantor Fitzgerald has the highest price target set, predicting CLDX will reach $67.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $21.00 for Celldex Therapeutics in the next year.
View the latest price targets for CLDX.

What is the current consensus analyst rating for Celldex Therapeutics?

Celldex Therapeutics currently has 2 sell ratings, 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CLDX.

What other companies compete with Celldex Therapeutics?

Other companies that are similar to Celldex Therapeutics include Alkermes, Ligand Pharmaceuticals, Amicus Therapeutics, Zenas BioPharma and MannKind. Learn More about companies similar to Celldex Therapeutics.

How do I contact Celldex Therapeutics' investor relations team?

Celldex Therapeutics' physical mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company's listed phone number is (908) 454-7120 and its investor relations email address is [email protected]. The official website for Celldex Therapeutics is www.celldex.com. Learn More about contacing Celldex Therapeutics investor relations.